Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC.

J Endocrinol Invest. 1997 Dec;20(11):648-58. Review.

PMID:
9492103
2.

Nuclear medicine therapy of pheochromocytoma and paraganglioma.

Troncone L, Rufini V.

Q J Nucl Med. 1999 Dec;43(4):344-55. Review.

PMID:
10731785
3.

131I-MIBG therapy of neural crest tumours (review).

Troncone L, Rufini V.

Anticancer Res. 1997 May-Jun;17(3B):1823-31. Review.

PMID:
9179240
4.

Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.

Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, Ell PJ.

Clin Oncol (R Coll Radiol). 2003 Jun;15(4):193-8. Review.

PMID:
12846498
5.

Radiopharmaceutical treatment of pheochromocytomas.

Sisson JC.

Ann N Y Acad Sci. 2002 Sep;970:54-60. Review.

6.

[Treatment of malignant pheochromocytoma with 131I MIBG: a long survival].

Arias Martínez N, Barbado Hernández FJ, Couto Caro R, Gil Guerrero L, Coronado Poggio M, Navarro T, Gómez Cerezo J, Casal Esteban V, Vázquez Rodríguez JJ.

An Med Interna. 2003 Nov;20(11):575-78. Review. Spanish.

PMID:
14624651
7.

[Recent progress in radionuclide therapy].

Kasagi K, Iwata M, Misaki T, Konishi J, Sakahara H.

Nihon Igaku Hoshasen Gakkai Zasshi. 2000 Nov;60(13):729-37. Review. Japanese.

PMID:
11140321
8.

[Therapeutic possibilities in metastatic pheochromocytoma].

Vierhapper H, Raber W.

Zentralbl Chir. 1997;122(6):494-7. Review. German.

PMID:
9334119
9.

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.

Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM.

Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83. Review.

PMID:
12153595
10.

131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.

Tepmongkol S, Heyman S.

Med Pediatr Oncol. 1999 Jun;32(6):427-31; discussion 432. Review.

PMID:
10358701
11.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
12.

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB.

Endocr Relat Cancer. 2007 Sep;14(3):569-85. Review.

13.

(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.

van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP.

Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501. doi: 10.1111/cen.12341. Epub 2013 Nov 19. Review.

PMID:
24118038
14.

Clinical management of malignant adrenal tumors.

Kopf D, Goretzki PE, Lehnert H.

J Cancer Res Clin Oncol. 2001;127(3):143-55. Review.

PMID:
11260859
15.

I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.

Carrasquillo JA, Pandit-Taskar N, Chen CC.

Semin Nucl Med. 2016 May;46(3):203-14. doi: 10.1053/j.semnuclmed.2016.01.011. Review.

PMID:
27067501
16.

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.

Wiseman GA, Kvols LK.

Semin Nucl Med. 1995 Jul;25(3):272-8. Review.

PMID:
7570046
17.

Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.

Castellani MR, Aktolun C, Buzzoni R, Seregni E, Chiesa C, Maccauro M, Aliberti GL, Vellani C, Lorenzoni A, Bombardieri E.

Q J Nucl Med Mol Imaging. 2013 Jun;57(2):146-52. Review.

PMID:
23822990
18.

[Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

Défachelles AS, Cougnenc O, Carpentier P.

Bull Cancer. 2011 May;98(5):559-69. doi: 10.1684/bdc.2011.1353. Review. French.

20.

Update on basic research and clinical experience with metaiodobenzylguanidine.

Beierwaltes WH.

Med Pediatr Oncol. 1987;15(4):163-9. Review.

PMID:
3309601

Supplemental Content

Support Center